Related Experiment Videos

Serum complement levels before and after the onset of acute post-streptococcal glomerulonephritis. A case report

C F Strife1, T J Forristal, J Forristal

  • 1Division of Nephrology, Children's Hospital Medical Center, Cincinnati, Ohio 45229-2899.

Insights

Complement activation, particularly via the alternative pathway, appears to precede the clinical onset of acute post-streptococcal glomerulonephritis (APSGN). This early activation involves specific complement components before nephritis symptoms manifest.

Area of Science:

  • Immunology
  • Nephrology
  • Pediatrics

Background:

  • Acute post-streptococcal glomerulonephritis (APSGN) is a common renal disease in children.
  • Low serum levels of complement components C3, C5, and properdin are characteristic of the acute phase of APSGN, indicating significant complement system activation.
  • The specific timing and predominant pathway of complement activation in relation to clinical APSGN onset remain areas of investigation.

Observation:

  • A case study of a child hospitalized with erysipelas who subsequently developed APSGN was monitored.
  • Serum samples were analyzed for complement component levels before and after the clinical onset of nephritis.
  • Initial serum samples, taken before nephritis symptoms, showed low properdin levels and normal C3/C5, despite detectable C3 splitting activity.

Findings:

  • The patient exhibited low serum C3, properdin, and C5 levels after the clinical onset of gross hematuria, consistent with typical APSGN.
  • Early complement activation, evidenced by low properdin and C3 splitting activity, was detected prior to the overt clinical presentation of APSGN.
  • Complement activation, predominantly via the alternative pathway, appears to initiate before the development of clinical nephritis.

Implications:

  • These findings suggest that complement activation is an early event in the pathogenesis of APSGN.
  • Understanding the temporal sequence of complement activation may offer insights into potential early diagnostic markers for APSGN.
  • Targeting the alternative complement pathway could be a future therapeutic strategy for preventing or mitigating APSGN.

Related Concept Videos